Acomplia - Zimulti

Introduction and Overview
Obesity is on the rise in many countries in the world, which has created a need for pharmaceutical grade drugs, which can help, those who are chronically obese and require medical intervention lose weight safely. This is where Acomplia comes into play, because it is a pharmaceutical grade anorectic anti-obesity drug sold by Sanofi-Aventis in the UK and Sanofi-Synthelabo in Denmark. As of yet it is not currently available on the US, because it has not received clearance from the proper government agencies.
Ingredients at a Glance
Acomplia’s main ingredient is Rimonabant, which is a CB1 cannabinoid receptor antagonist, which is a complicated way of saying that it can provide users with a reduction in appetite. This is the first “CB1 cannabinoid receptor antagonist” to be approved anywhere in the world to treat obesity. However, its use is contingent upon the inclusion of a healthy diet and exercise into the lifestyle of users.
Ingredients In Focus
Many view Rimonabant and by extension Acomplia to be the new “wonder drug” of weight loss. It has gone through a variety of clinical studies in which patients took this drug for a year, and the results were very good in terms of weight loss, improved insulin sensitivity, and increases in HDL cholesterol. These studies provided the information that precipitated its approval in Europe. However, many are watching carefully because it is the first of its kind and works very differently than any other obesity drug. It directly affects a part of the brain called the endocannabiniod system, which regulates relaxation, pain tolerance and pleasure. No one knows how directly interfering with the operation of this system will affect users in the long term. The endocannabiniod system protects the brain during any type of brain trauma; some experts have suggested that use of this product may well block the system from doing its job when it is needed during times of trauma.
Diet Lifestyle
Positives
• May help with true obesity
Negatives
• Must be medically supervised
• Possible side effects both known and unknown
• Not currently available in US at time of review
Final Thoughts
Acomplia is clearly a pharmaceutical drug that is targeted toward those who are chronically and severely obese, and not for those who simply need to lose weight. As mentioned earlier it does have some known side effects such as depression, anxiety and nausea. It also affects the brain in a very new way which may eventually result in some other issues and side effects. It is for this reason we firmly believe that the use of this drug must be medically supervised. Nevertheless, this drug is not currently approved for use in the, US for a variety of reasons. As mentioned earlier, it is available from over seas distributors; however, we can not recommend nor support the acquisition of this drug through this method. For those who are not obese and who want to address issues around weight loss there are other holistically based and safe methods available to them. For instance, many consumers have achieved outstanding results with the use of Hoodia, an appetite suppressant, which has been proven to be able to convince the brain that the stomach is full – naturally and safely.